LoginRegister

    Glenmark gets USFDA approval for cholesterol drug

    Written by Ruby Khatun Khatun   |  
    Glenmark gets USFDA approval for cholesterol drug

    New Delhi: Glenmark Pharmaceuticals has received final approval from the US health regulator for Colesevelam Hydrochloride for oral suspension, used to lower cholesterol levels in the blood.


    The approval has been granted by the United States Food and Drug Administration (USFDA) in the strengths of 1.875 grams/packet and 3.75 grams/packet, the company said in a BSE filing today.

    The approved product is a generic version of Daiichi Sankyo Inc's Welchol.

    Quoting IQVIA sales data for the 12-month period ended May 2018, the company said Welchol achieved annual sales of around USD 73 million.

    The company's current portfolio consists of 138 products authorized for distribution in the US market, and 62 Abbreviated New Drug Applications (ANDAs) are pending approval with the USFDA, it added.
    abbreviated new drug applicationsapprovalcholesterol drugcholesterol lowering drugcolesevelam hydrochlorideDaiichi Sankyogeneric versionGlenmarkGlenmark PharmaGlenmark Pharmaceuticalslower cholesterol levelsOral SuspensionUnited States Food and Drug AdministrationUSFDAWelcholWelchol tablets
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X